Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bicycle Partners With Biogen Spinout Against Rare Blood Disorders

Executive Summary

Bicycle Therapeutics and Biogen spinoff Bioverativ have teamed up to develop novel treatments for hemophilia and sickle cell disease under a multi-million-dollar discovery and development agreement.


Related Content

Bioverativ: More Than Just A Hemophilia Company
Deal Watch: AstraZeneca Offloads US Anesthesiology Portfolio To Aspen
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
AstraZeneca Puts Bicycles To Work In Multitarget Deal
Why Kevin Lee Left Pfizer To Push Bicycles


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts